Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer

Stock Information for Kintara Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kintara Therapeutics Inc.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates NVEI, CHX, KTRA, ABIO
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - KTRA, CHX, NVEI, ADTH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, KTRA
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.